Page last updated: 2024-12-05

3,4-pyridinedicarboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-Pyridinedicarboxylic acid (3,4-PDA) is a heterocyclic dicarboxylic acid with potential applications in various fields. It is a versatile building block for the synthesis of pharmaceuticals, agrochemicals, and functional materials. 3,4-PDA has been investigated for its biological activities, such as its anti-cancer, anti-bacterial, and anti-inflammatory properties. Its coordination chemistry is also of interest due to its ability to form stable complexes with metal ions, leading to the development of novel catalysts, sensors, and luminescent materials. 3,4-PDA can be synthesized through various methods, including the oxidation of 3,4-dimethylpyridine or the reaction of pyridine with carbon dioxide. Research on 3,4-PDA focuses on exploring its potential as a precursor for the synthesis of new compounds, investigating its biological activities, and developing its applications in various fields.'

3,4-pyridinedicarboxylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10273
CHEMBL ID261326
CHEBI ID46860
SCHEMBL ID71335
MeSH IDM000606842

Synonyms (51)

Synonym
AC-1183
pyridine carboxylate, 6e
bdbm26117
pyridine-3,4-dicarboxylic acid
inchi=1/c7h5no4/c9-6(10)4-1-2-8-3-5(4)7(11)12/h1-3h,(h,9,10)(h,11,12
nsc178
nsc-178
cinchomeronic acid
chinchomeronic acid
490-11-9
3,4-pyridinedicarboxylic acid
3,4-pyridinedicarboxylic acid, 97%
CHEBI:46860 ,
OPREA1_020498
CHEMBL261326
AKOS000280879
P0682
STK801438
A7359
3,4-pyridinedicarboxylicacid
BBL010076
AM62714
pyridine-3,4-dicarboxylicacid
nsc 178
unii-7389uzw5dy
einecs 207-705-4
7389uzw5dy ,
FT-0623820
cinchomeronic acid [mi]
CL0113
BP-21355
SCHEMBL71335
3,4-pyridine dicarboxylic acid
3,4-pyridine-dicarboxylic acid
pyridine 3,4-dicarboxylic acid
FG-0458
SY004289
mfcd00006392
cambridge id 5153935
STR01772
Q-101246
2,3-pyridinedicarboxylic acid #
F0001-1280
DTXSID70197653
cinchomeronsaure
CS-D1674
Q27120712
EN300-69982
pyridin-3,4-dicarbonsa currencyure
3.4-pyridinedicarboxylic acid
Z1123696308
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridinedicarboxylic acidAny member of the class of pyridines carrying two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)10,000.00000.20001.95696.3096AID1798635
Beta-lactamase Aeromonas hydrophilaKi1,100.00004.50005.10005.7000AID323626
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1798635FDH Coupled Inhibition Assay from Article 10.1021/jm800936s: \\Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases.\\2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID323626Inhibition of Aeromonas hydrophila beta lactamase CphA by competitive inhibition assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID344916Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess 2-oxoglutarate and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID323627Inhibition of Aeromonas hydrophila beta lactamase CphA N116H-N220G mutant by competitive inhibition assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323614Inhibition of Pseudomonas aeruginosa 101/1477 metallo beta lactamase IMP1 expressed in in Escherichia coli assessed as residual enzyme activity at 100 uM in presence of zinc chloride2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323615Inhibition of Bacillus cereus metallo beta lactamase Bc2 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323618Inhibition of Aeromonas hydrophila metallo beta lactamase CphA assessed as residual enzyme activity at 100 uM in absence of zinc2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323613Inhibition of Pseudomonas aeruginosa 101/1477 metallo beta lactamase IMP1 expressed in in Escherichia coli assessed as residual enzyme activity at 100 uM in absence of zinc2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323616Inhibition of metallo beta lactamase VIM2 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323620Inhibition of Legionella gormani beta lactamase metallo FEZ1 expressed in Escherichia coli assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323617Inhibition of metallo beta lactamase VIM4 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID323619Inhibition of Stenotrophomonas maltophilia metallo beta lactamase L1 assessed as residual enzyme activity at 100 uM2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Competitive inhibitors of the CphA metallo-beta-lactamase from Aeromonas hydrophila.
AID344917Inhibition of 2-oxoglutarate-dependent human JMJD2E in presence of excess H3K9me3 peptide and 10 uM Fe2 by FDH coupled assay2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.32 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]